ImmuPharma plc (LON:IMM – Get Free Report)’s share price was down 11.4% on Friday . The company traded as low as GBX 2.71 ($0.03) and last traded at GBX 3.10 ($0.04). Approximately 30,011,082 shares traded hands during trading, an increase of 48% from the average daily volume of 20,325,906 shares. The stock had previously closed at GBX 3.50 ($0.04).
ImmuPharma Stock Performance
The stock has a market capitalization of £18.82 million, a PE ratio of -452.00 and a beta of 1.53. The business’s 50-day moving average is GBX 1.40 and its two-hundred day moving average is GBX 1.65.
About ImmuPharma
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Further Reading
- Five stocks we like better than ImmuPharma
- What Are Dividend Contenders? Investing in Dividend Contenders
- Zymeworks in Focus for Insider Activity: Catalysts Ahead
- How to Choose Top Rated Stocks
- Kura Sushi Stock Dips Into a Hot Buying Opportunity
- Basic Materials Stocks Investing
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
